22347-71-3

Basic information

• Product Name: 3,4-dihydro-2H-pyran-2-ylmethyl acetate
• Synonyms: 2H-pyran-2-methanol, 3,4-dihydro-, acetate; 3,4-Dihydro-2H-pyran-2-ylmethyl acetate
• CAS NO: 22347-71-3
• Molecular Formula: C₈H₁₂O₃
• Molecular Weight: 156.1791
• Mol File: 22347-71-3.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 213°C at 760 mmHg
• Flash Point: 80.8°C
• Density: 1.052g/cm³
• Vapor Pressure: 0.168mmHg at 25°C
• Refractive Index: 1.451
• CAS DataBase Reference: 3,4-dihydro-2H-pyran-2-ylmethyl acetate(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-dihydro-2H-pyran-2-ylmethyl acetate(22347-71-3)
• EPA Substance Registry System: 3,4-dihydro-2H-pyran-2-ylmethyl acetate(22347-71-3)

Safety Data

• Hazardous Substances Data: 22347-71-3(Hazardous Substances Data)

Upstream product

• 3749-36-8 2-hydroxymethyl-3,4-dihydro-2H-pyran 
• 75-36-5 acetyl chloride 
• 100-73-2 acrolein dimer 
• 108-24-7 acetic anhydride 
• 124654-48-4 trans-6-(phenylsulphonyl)-tetrahydro-2H-pyran-2-methanol acetate 

Downstream Products

• 124654-49-5 trans-2-(benzenesulphonyl)-6-<(tert-butyldiphenylsilyloxy)methyl>tetrahydro-2H-pyran 
• 124654-38-2 trans-methyl 6-<(tert-butyldiphenylsilyloxy)methyl>tetrahydro-α,α-dimethyl-2H-pyran-2-acetate 
• 124654-38-2 cis-methyl 6-<(tert-butyldiphenylsilyloxy)methyl>tetrahydro-α,α-dimethyl-2H-pyran-2-acetate 
• 124654-50-8 trans-6-(benzenesulphonyl)tetrahydro-2H-pyran-2-methanol 
• 34670-51-4 acide (3RS-5RS) diamino-3,6 hydroxy-5 hexanoique 

Relevant articles and documents

Enantiopure purpurosamine C type glycosyl donors an improved access from rac-Acrolein dimer - Biocatalytic resolution

An improved synthetic access to a suitably 'protected' purpurosamine C type glycosyl donor (11, analogously ent-11) starting from racemic 3,4-dihydro-2H-pyran-2-carbaldehyde (rac-1, acrolein dimer) implies an 'indirect aziridination protocol' and a biocatalytic resolution step (acetate hydrolysis, ee > 98). The latter's stereochemical course is confirmed by a highly α-selective glycosylation with an acceptor of known absolute configuration.

-

-

Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses thereof

Disclosed are an antibody drug conjugate IB, which uses ether linkages for connection, and improves the water solubility, stability and cytotoxicity in vivo and in intro, and an intermediate, a pharmaceutical composition, and uses of the antibody drug conjugate. The antibody drug conjugate has simple synthetic steps and a high yield.

MODULAR SYNTHESIS OF AMINOGLYCOSIDES

The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds and the compounds used in such preparations.